Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

BMS Sees Zeposia As Safer Oral Option In Ulcerative Colitis

Efficacy Comparable To Gilead/Galapagos JAK Inhibitor Filgotinib

Executive Summary

Bristol Myers Squibb reported detailed results from the Phase III TRUE NORTH study that show durable remissions in a patient population that switches therapies due to loss of response. 

You may also be interested in...



Zeposia’s Ulcerative Colitis Approval Provides BMS’s Beachhead Into GI

The second US approval for the S1P receptor agonist brings Bristol into the gastrointestinal space, and is just the starting point for the pharma in that arena, the company told Scrip.

Biotech’s Double-Edged Sword: Extraordinary Funding Run Contributes To Talent Crisis

Finding good leaders always has been hard, but record-breaking VC investment and IPOs, COVID-19 and diversity initiatives have compounded the growing problem. 

Arena Updates Etrasimod Timelines, Introduces New Drug Candidate

CEO Amit Munshi told the J.P. Morgan meeting the company will double the size of its clinical-stage cardiovascular disease pipeline with the addition of temanogrel.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

SC143118

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel